Dried Blood Spot Collection Cards Market
Report ID: SQMIG35A3381
Report ID: SQMIG35A3381
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3381 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
155
|Figures:
78
Global Dried Blood Spot Collection Cards Market size was valued at USD 245.8 Million in 2024 and is poised to grow from USD 252.68 Million in 2025 to USD 315.15 Million by 2033, growing at a CAGR of 2.8% during the forecast period (2026-2033).
The primary driver of the dried blood spot collection cards market is the accelerating shift toward decentralized specimen collection that reduces cost, logistical complexity and biosafety risks compared with venous sampling. Dried blood spot (DBS) cards are used to collect, dry, transport, and store tiny amounts (microliter volumes) of whole blood on filter papers; these cards have become critical for the purposes of laboratory analysis of both newborns and older children (via epidemiological surveys) and for monitoring the therapeutic drug levels of patients in remote areas using home health care services. The market for DBS cards developed out of Guthrie test cards used for neonatal screening to standardized products (e.g., Whatman 903 or PerkinElmer); continued improvements in the manufacture of DBS cards and regulatory guidance have also improved their acceptance for use by public health programs in low-resource settings.
Building on growing acceptance is a key factor propelling the dried blood spot cards market is analytical and regulatory validation that enables reliable, high-sensitivity assays across clinical and research applications. When laboratories demonstrate reproducible extraction and quantitation by LC-MS/MS, PCR or immunoassays, clinicians and regulators gain confidence, which increases adoption in newborn screening, HIV Sero surveillance, COVID-19 serology and decentralized clinical trials. That wider use drives manufacturing scale, lowers unit costs and encourages industry partnerships to develop home-collection kits and standardized protocols, thereby creating opportunities in low- and middle-income countries and telemedicine where cold-chain-free logistics, simplified sampling significantly reduce barriers to care.
How is AI Enhancing Quality Control in the Dried Blood Spot Collection Cards Market?
The quality control of dried blood spot (DBS) collection cards is being enhanced via AI through automation of visual assessments and standardization of sample evaluations. Automation of DBS samples through AI-assisted image evaluations, and the use of machine learning that flags samples with poor absorption or contamination, as well as integration with automated card handling to improve manual error reduction, is being explored. The market is moving toward decentralized testing and higher throughput laboratories that need reliable at home sampling and low rejection rates. Real world pilots show vision guided validators and automated workflows that photograph cards, apply AI rules, and pass only compliant samples to downstream processing which makes operations more consistent and faster.
Tasso Inc February 2025, launched a next generation dried blood spot collection system that improves sample consistency. That improvement makes image based AI inspection and automated workflows more effective and supports greater efficiency and wider adoption of microsampling.
Market snapshot - (2026-2033)
Global Market Size
USD 245.8 Million
Largest Segment
Whatman/Cellulose-Based Cards
Fastest Growth
Specialized DBS Cards
Growth Rate
2.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global dried blood spot collection cards market is segmented by product type, application, sample type, end user, distribution channel and region. Based on product type, the market is segmented into Whatman/cellulose-based cards, FTA cards, protein saver cards, specialized DBS cards and others. Based on application, the market is segmented into newborn screening, infectious disease testing, therapeutic drug monitoring, genetic & genomic testing, toxicology testing, clinical research & biobanking, veterinary diagnostics and others. Based on sample type, the market is segmented into whole blood collection, plasma separation collection, serum spot collection and multi-analyte sample collection. Based on end user, the market is segmented into hospitals & diagnostic laboratories, research & academic institutes, pharmaceutical & biotechnology companies, public health & government organizations, contract research organizations (CROs) and home care & remote sampling users. Based on distribution channel, the market is segmented into direct sales, distributors & dealers and online sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
FTA cards hold a significant share due to their chemically treated matrix stabilizes nucleic acids and pathogens immediately upon collection, enabling reliable molecular testing without cold chain. The natural preservation of samples helps to reduce both the degradation of the sample and assay variations, thus leading to an increased use by diagnostic laboratories and biobanks. Familiarity with regulatory requirements and compatibility with high-sensitivity workflows will also push labs and biobanks toward purchasing these types of products. Transport ease and biosafety improvements will also reduce barriers to operation and will allow large-scale screening and monitoring.
One of the more recent and rapidly growing types of sample collection modalities is the Whatman/cellulose based card due to their cost-efficiency as well as their recognition as a reliable and familiar medium. As the industry has improved upon recovery of analytes from these sample collection devices, they have also begun to develop methods that allow these devices to be used for monitoring healthcare therapies and performing distributed testing, as well as for sample collection purposes. With low-cost and resiliency in the supply chain, use of these products for home collection of samples for testing and within resource-limited laboratories will also create new opportunities for routine tests.
Dried blood spot cards are the foundation of neonatal metabolic and congenital disorder programs, creating standardized collection workflows and high-quality quality control throughout the healthcare system. This established role provides a guaranteed demand from public health programs and laboratories, so manufacturers are incentivized to make their products reliable and consistent across batches. The clinical imperative for early diagnosis drives investment in validated materials and supports integration of cards into long term biobanking and follow up testing pathways.
Conversely, infectious disease testing is emerging as the most rapidly expanding area as molecular diagnostics and surveillance programs increasingly adopt DBS for remote, stable sample collection. Improvements made to pathogen detection through increased assay sensitivity and regulations have expanded the uses of testing by encouraging private investment to improve specific cards and logistics, which enable the possibilities of using these tests for surveillance, responding to an outbreak, and testing in a decentralized way.
To get detailed segments analysis, Request a Free Sample Report
The convergence of strong clinical infrastructure, widespread and early adoption of dried blood spot collection cards for newborn screening and decentralized testing, and collaborative efforts among manufacturers, reference laboratories, and healthcare systems, North America will continue to dominate the worldwide dried blood spot collection market. A developed regulatory environment with clear pathways for clinical validation and reimbursement will de-risk diluted blood spot card adoption for both providers and payers. The extensive R&D capacity of leading North American dried blood spot manufacturers is facilitating continuous improvements in card materials, analytical performance, and data integration capabilities. Well-established logistics and laboratory systems in North America enable reliable specimen transport and high-quality analyzable specimens. The market leader is further consolidated in North America by numerous public and private funding sources, strategic partnerships, and multi-disciplinary research consortia. Highly aware clinicians and education initiatives specifically focused on dried blood spot testing workflows will help raise the profile of the dried blood spot collection card, while the integration of dried blood spot collection into the ecosystem of telehealth and home sampling programs will provide additional patient access and sustain demand.
Dried blood spot collection cards industry trends in United States is supported by established clinical research networks, characteristic newborn screening programs, and strong laboratory infrastructure. Since large manufacturers frequently collaborate with diagnostic laboratories and academic centers to improve sampling methods and validation procedures, reimbursement acceptance and efficient shipping/logistics for stored specimens supports decentralized testing and at-home collection options. Emerging innovations in material technology and integration with EHRs continue to enhance clinical utility; cross-stakeholder partnerships facilitate greater acceptance within care environments.
Dried blood spot collection cards market in Canada drives the dried blood spot (DBS) card market in Canada; the most important are coordinated programs from different levels of government, high levels of use in newborn screening, and the connections between provincial labs and research institutions. The focus on patient-centered and fielding samples aids in supporting geographic areas with large populations and providing access to specialized types of testing. The supplier of DBSs has partnered with the provincial public laboratories to create uniform quality assurance inspection protocols. The focus on interoperability and the involvement of stakeholders will allow for further growth into clinical and research use.
The rapid growth of the dried blood spot collection cards industry in Europe is being fueled by three primary trends: a rising focus on decentralized diagnostics, the creation of coordinated public health screening programs, and a changing clinical pathway model that utilizes less invasive sampling methods. Diagnostic manufacturers and research institutions have a strong presence in this space, providing an ideal environment for conducting validation studies and product improvements. In addition, there is active collaboration among countries to establish standards of care and improve quality control, thereby reducing fragmentation that often exists among national healthcare systems. Additionally, telemedicine and remote patient monitoring have become increasingly common; therefore, there is increased interest in decentralizing clinical trials, which further supports the adoption of dried blood spot testing as a method of diagnosis. Policymaker support (i.e., through access and cost to testing) and targeted pilot projects and partnerships between diagnostic manufacturers and healthcare providers will help accelerate market growth and develop a competitive marketplace across multiple European countries. Investment in harmonized training and accredited laboratories as well as integrating dried blood spot testing into routine clinical workflows will increase providers’ confidence in using this technology. Visibility in specialist care settings and newborn screening programs provides an opportunity for continued growth within the dried blood spot collection card market in European countries.
Dried blood spot collection cards market in Germany has an advanced medical technology (medtech) enterprise, a sizable laboratory system, and strict quality standards for diagnostic testing, which support the development of the dried blood spot collection card industry. Manufacturers validate the performance of their cards through cooperation with clinical laboratories and academic institutions, and align card use with workflows in hospital settings. A focus on analytical performance and integration with laboratory information systems improves the clinical acceptance of dried blood spot collection cards. Cooperation and collaboration between industry, academic institutions, and public health agencies continue to bolster Germany's position as a leader in advanced diagnostic collection techniques.
Dried blood spot collection cards market in the United Kingdom is growing due to a focus on community based diagnostics, digital integration of health care, and decentralising care delivery. The use of dried blood spots for diagnostic testing will continue to expand as collaborative efforts between public health agencies, clinical laboratories and innovative suppliers increase the speed of pilot programs and their uptake. The emphasis on patient convenience, remote monitoring and clear pathways to clinical validation will support widespread use of dried blood spots across both primary care and specialist services.
Dried blood spot collection cards market trends in France are growing in the field of dried blood spot (DBS) collection-based testing. Factors contributing to this growth include targeted public health programs, increased participation by clinical researchers, and collaborations between diagnostic companies and academic institutions. Some examples of this evolution include pilot projects showing the usefulness of DBS for neonatal screening and long-term monitoring of chronic diseases via decentralized methods of collecting samples. Regulatory pathways continue to be adjusted to encourage further validation and use on a broader scale within the clinical setting. Through efforts focused on standardization, quality control, and integration into existing laboratory reporting systems, clinician confidence in the use of DBS is being built and momentum is developing.
The dried blood spot collection card market in Asia Pacific is rapidly growing due to a combination of localized manufacturing expansion, governmental public health initiatives, and increased collaboration with global diagnostic partners. There is also a growing focus on diagnostic research and pilot screening programs for the purpose of localizing product development and validation. Furthermore, with improved supply chain capability and expanded laboratory capacity, decentralized sampling is becoming increasingly viable across various geographies. Digital health technology adoption and telemedicine platforms are allowing for remote collection and reporting. Regulatory and quality assurance frameworks are maturing in a number of markets allowing for greater clinical acceptance. Additionally, regional centres of excellence and academic partner relationships are accelerating innovation, thereby establishing the region's growing impact on the global market landscape. Developments in the market are supported by local adaptations of products to match region-specific clinical practices and the training of laboratory staff. The increased awareness of clinical research and the establishment of cross-border distribution agreements will lead to even greater integration of the market across Asia Pacific.
Dried blood spot collection cards market growth in Japan will be driven by a focus on advanced technologies, high-quality analysis, and aligning the card collections with precision medicine initiatives in Japan. Diagnostic manufacturers are teaming with research hospitals and clinical labs to validate new card materials and analytical methods. Data integration and linking with electronic health records promote clinical research applications and monitoring. Patient-centric sampling and associated regulations support the use of dried blood spot collection cards in both clinical and research settings.
Dried blood spot collection cards market outlook in South Korea is expected to experience significant growth due to several factors, including advances in biotechnological and manufacturing innovations; collaborative partnerships between diagnostic manufacturers and research institutions to develop innovative products; and a focus on producing high-quality products that will be accepted by consumers. In addition, domestic manufacturers are committed to producing high-performance materials and utilizing efficient supply chains to meet the needs of the Korean healthcare system. The integration of dried blood spot collection card systems with digital health platforms and rigorous validations in laboratories are increasing the clinical credibility of these products and helping to facilitate more widespread adoption by hospitals and communities.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Demand for Remote Testing
Increasing Chronic Disease Screening
Regulatory Acceptance Variability
Material Shortages Affecting Production
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in Global Dried Blood Spot Collection Cards features incumbent diagnostic suppliers and newer microsampling firms competing on regulatory-compliant volumetric sampling. Competition is driven by decentralized clinical trials and diagnostics adoption, with firms pursuing acquisitions, lab partnerships and product innovation such as Trajan’s acquisition of Neoteryx, Capitainer’s qDBS and SEP10 product rollouts, and PerkinElmer’s DBS assay integrations to secure lab workflows.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global dried blood spot collection cards market is propelled primarily by the shift toward decentralized specimen collection that lowers costs, logistics and biosafety burdens, while a second major driver is growing analytical and regulatory validation enabling high-sensitivity assays across clinical and surveillance settings. Adoption remains constrained by inconsistent regulatory acceptance across jurisdictions that complicates validation and procurement. North America leads the market due to a mature clinical infrastructure, the establishment of new pediatric screening programs, and strong partnerships between industry and laboratories. Newborn screening dominates programs with dull workflows, best-in-class surveillance and public health funding, validating DBS cards for a steady rise in decentralized initiatives and biobanking.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 245.8 Million |
| Market size value in 2033 | USD 315.15 Million |
| Growth Rate | 2.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Dried Blood Spot Collection Cards Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Dried Blood Spot Collection Cards Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Dried Blood Spot Collection Cards Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Dried Blood Spot Collection Cards Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Dried Blood Spot Collection Cards Market size was valued at USD 245.8 Million in 2024 and is poised to grow from USD 252.68 Million in 2025 to USD 315.15 Million by 2033, growing at a CAGR of 2.8% during the forecast period (2026-2033).
Competitive landscape in Global Dried Blood Spot Collection Cards features incumbent diagnostic suppliers and newer microsampling firms competing on regulatory-compliant volumetric sampling. Competition is driven by decentralized clinical trials and diagnostics adoption, with firms pursuing acquisitions, lab partnerships and product innovation such as Trajan’s acquisition of Neoteryx, Capitainer’s qDBS and SEP10 product rollouts, and PerkinElmer’s DBS assay integrations to secure lab workflows. 'QIAGEN', 'Ahlstrom', 'Eastern Business Forms', 'PerkinElmer', 'Roche Diagnostics', 'Shimadzu Corporation', 'ARCHIMEDlife', 'CENTOGENE', 'Pall Corporation', 'GenTegra', 'Lipomic Healthcare', 'Surgeine Healthcare', 'Synergy Medical Systems', 'Thomas Scientific', 'CAMAG', 'Capitainer', 'Spot On Sciences', 'Neoteryx', 'Cerba Research', 'Trajan Scientific and Medical'
The growing preference for minimally invasive sample collection and remote diagnostics has expanded the applicability of dried blood spot cards across clinical and consumer settings. Their ease of use enables broader reach into underserved populations and supports continuity of monitoring outside traditional laboratories. Longer sample stability and simplified transport reduce logistical barriers, encouraging adoption by healthcare providers and research organizations seeking more flexible specimen handling. Together, these attributes lower implementation friction and make dried blood spot collection an attractive option for expanding testing programs and longitudinal studies.
Decentralized Testing Adoption: Growing adoption of decentralized testing models is driving demand for dried blood spot collection cards as they enable patient-centered sample collection outside traditional facilities. Stakeholders prioritize ease of use, transport resilience, compatibility with remote workflows to expand screening, chronic disease monitoring, and community-based studies. Manufacturers and service providers are aligning product design, training resources, and distribution channels to support collection scenarios, while clinicians and public health programs increasingly consider these cards to improve access, retention, continuity of diagnostic services.
Why does North America Dominate the Global Dried Blood Spot Collection Cards Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
